Intellia's Q1 Loss Narrows, Lonvo-z Phase 3 Positive, FDA Holds Lifted for Nex-z Trials
NTLA has more than doubled off its 52-week low of $6.83.
Summary
Intellia Therapeutics reported Q1 2026 results with revenue of $15.0M and a diluted EPS loss of $(0.81). While revenue declined, the net loss improved significantly to $96.2M from $114.3M in the prior year. This earnings report follows the company's recent successful public offering, which netted approximately $194.6 million, further strengthening its financial position. Beyond the financials, the company announced critical positive business updates: successful Phase 3 HAELO results for lonvo-z, initiation of a rolling BLA for lonvo-z targeting a H1 2027 launch, and the lifting of FDA clinical holds for nex-z trials. These clinical and regulatory advancements, coupled with reduced R&D spending and an extended cash runway into 2028, are highly material for a biotech company and significantly de-risk its pipeline and operations. Investors will be closely watching the progress of the lonvo-z BLA submission and the re-initiation of enrollment for the nex-z trials, as well as further updates on commercialization plans for lonvo-z.
At the time of this announcement, NTLA was trading at $13.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $6.83 to $28.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.